Track market-moving stories before they get noisy

Sprout Social, Inc. (SPT) Q1 2026 Earnings Call Transcript

Sprout Social: Record Q1, AI Fears Are Overdone

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in combination with zanzalintinib in STELLAR-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of th.

Key Takeaways Exelixis and Merck will study zanzalintinib plus Keytruda Qlex in phase III CRC trial STELLAR-316.EXEL plans to launch STELLAR-316 in mid-2026 for MRD-positive stage II/III colorectal cancer.Zanzalintinib NDA with Tecentriq in metastatic CRC faces FDA action date of Dec. 3, 2026. Exelixis (EXEL - Free Report) announced a clinical development collaboration with pharma giant Merck & Co. (MRK - Free Report) to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the planned phase III STELLAR-316 study for resected stage II/III colorectal cancer (CRC).

Under the agreement, Exelixis will sponsor the STELLAR-316 study, while Merck will provide Keytruda Qlex for use in the study.

Exelixis expects to initiate STELLAR-316 in mid-2026.

Year to date, Exelixis’ shares have risen 11.1% against the industry’s decline of  2.7%.

Image Source: Zacks Investment Research

More on EXEL’s Efforts to Advance ZanzalintinibZanzalintinib is a novel oral kinase inhibitor that inhibits the activity of the TAM kinases (TYRO3, AXL, MeR), MET and VEGF receptors.

The late-stage STELLAR-316 will evaluate zanzalintinib with and without Keytruda Qlex in patients with resected stage II/III CRC who, following definitive therapy, have tested positive for molecular residual disease (MRD+) and have no radiographic evidence of disease — a high-risk population with substantial unmet need.

Keytruda is approved for several types of cancer.

The collaboration with Merck adds external validation to the zanzalintinib program.

Earlier this year, Exelixis partnered with Natera (NTRA - Free Report) , a global leader in cell-free DNA and precision medicine, for this study.

Natera will supply its Signatera assay to identify eligible MRD-positive patients for enrollment, further integrating precision medicine into the program.

EXEL Seeks to Diversify Portfolio Beyond CabometyxZanzalintinib represents the company’s most significant near-term catalyst.

Exelixis’ new drug application seeking approval of zanzalintinib in combination with Roche’s (RHHBY - Free Report) Tecentriq for previously treated metastatic CRC is under review in the United States. The targeted population includes patients who have already received standard chemotherapy regimens, including fluoropyrimidine-, oxaliplatin- and irinotecan-based therapies, as well as anti-EGFR treatment for RAS wild-type disease.

The regulatory body set a target action date of Dec. 3, 2026.

A potential approval will broaden the company’s portfolio and reduce dependence on its lead drug, Cabometyx.

Roche’s Tecentriq is a cancer immunotherapy that is approved around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various types of cancer.

Exelixis collaborated with MRK in October 2024 to advance zanzalintinib.

In April 2026, MRK initiated LITESPARK-034, a phase III study evaluating zanzalintinib plus Welireg (belzutifan) versus Welireg and placebo in previously treated advanced renal cell carcinoma (RCC) patients who progressed after PD-1/L1 and VEGFR-TKI therapies.

This marks the second Merck-sponsored phase III study under the collaboration, following LITESPARK-033 (launched in December 2025), which is assessing the combination against cabozantinib in first-line advanced RCC post-adjuvant immunotherapy.

Exelixis also announced two additional studies of zanzalintinib — STELLAR-202, a planned phase II trial evaluating the drug in combination with MRK’s blockbuster drug Keytruda (pembrolizumab) as maintenance therapy in squamous non-small cell lung cancer, and a new expansion cohort in the ongoing phase Ib/II STELLAR-002 study assessing zanzalintinib plus docetaxel in metastatic castration-resistant prostate cancer patients with measurable disease.

EXEL’s Zacks Rank

– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX® (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago.

“The presentations at ASCO this year highlight the continued progress of our strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the development of zanzalintinib, our next oncology franchise molecule,” said Dana T. Aftab, Ph.D., Executive Vice President, Research and Development, Exelixis. “New analyses from the phase 3 CABINET pivotal trial that further reinforce the foundational role of CABOMETYX in patient care, and findings from the phase 3 STELLAR-303 pivotal trial evaluating our investigational therapy, zanzalintinib, in metastatic colorectal cancer, will be presented. These collective data sets are a testament to our team’s dedication to improving the standards of care for patients with cancer.”

Studies to be presented at the 2026 ASCO Annual Meeting include:

Abstract Title

Presentation

Session Title

Session Date/Time

Cabozantinib

A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801)

Oral Abstract #4500

Genitourinary Cancer – Kidney and Bladder

Friday, May 29
2:45 – 2:57 p.m. CDT

Interim analysis of CaboMain: A prospective, single-arm phase 2 clinical trial of cabozantinib as maintenance therapy for patients with “ultra-high-risk” pediatric solid tumors

Rapid Oral Abstract #10014

Pediatric Oncology II

Saturday, May 30
8:27 – 8:33 a.m. CDT

Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance A021602)

Poster #161 Abstract #4178

Gastrointestinal Cancer – Gastroesophageal, Pancreatic and Hepatobiliary

Saturday, May 30
9:00 a.m. – 12:00 p.m. CDT

Cabozantinib in high-grade neuroendocrine neoplasms

Poster #166 Abstract #4183

Gastrointestinal Cancer – Gastroesophageal, Pancreatic and Hepatobiliary

Saturday, May 30
9:00 a.m. – 12:00 p.m. CDT

EA3231: A randomized phase 3 study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with BRAF V600Em

Poster #589b Abstract #TPS6140

Head and Neck Cancer

Saturday, May 30
1:30 – 4:30 p.m. CDT

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial

Poster #7 Abstract #4528

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial

Poster #9 Abstract

#4530

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

PEMBROCABOSARC: A phase 2 trial combining pembrolizumab and cabozantinib in patients with advanced undifferentiated pleomorphic sarcoma

Rapid Oral Abstract

#11514

Sarcoma

Sunday, May 31
4:42 – 4:48 p.m. CDT

MAIN-CAV: Phase 3 randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001)

Rapid Oral Abstract #4514

Genitourinary Cancer – Kidney and Bladder

Monday, June 1
8:00 – 8:06 a.m. CDT

Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non-clear cell renal cell carcinoma (nccRCC)

Rapid Oral Abstract

#4521

Genitourinary Cancer – Kidney and Bladder

Monday, June 1
9:12 – 9:18 a.m. CDT

Survival outcomes of cabozantinib treatment with and without immune checkpoint inhibition in patients with heavily pretreated advanced sarcoma

Poster #341 Abstract #11551

Sarcoma

Monday, June 1
1:30 – 4:30 p.m. CDT

Safety and feasibility of cabozantinib (CABO) in combination with cisplatin, doxorubicin, and high-dose methotrexate (MAP) in patients with newly diagnosed high-risk osteosarcoma (OS)

Poster #281 Abstract #10030

Pediatric Oncology

Monday, June 1
1:30 – 4:30 p.m. CDT

Zanzalintinib

Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial

Poster #341 Abstract #3574

Gastrointestinal Cancer – Colorectal and Anal

Saturday, May 30
9:00 a.m. – 12:00 p.m. CDT

ZAMBONI: A phase 2 study of zanzalintinib for metastatic clear cell renal cell carcinoma with bone metastases previously treated with immune checkpoint inhibitors

Poster #110b Abstract #TPS4634

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

A phase 2 trial of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma (EXPLORE-RCC)

Poster #108a Abstract

#TPS4629

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti-PD-(L)1 therapy

Poster #110a Abstract #TPS4633

Genitourinary Cancer – Kidney and Bladder

Sunday, May 31
9:00 a.m. – 12:00 p.m. CDT

About CABOMETYX® (cabozantinib)
In the U.S., CABOMETYX tablets are approved as monotherapy for the treatment of patients with advanced RCC and in combination with nivolumab as a first-line treatment for patients with advanced RCC; for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible; for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET; and adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET. CABOMETYX tablets have also received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: CABOMETYX can cause severe and fatal hemorrhages. The incidence of Grade 3-5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, each occurred in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or GI perforation.

Thromboembolic Events: CABOMETYX can cause arterial or venous thromboembolic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events.

Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. In CABINET (n=195), hypertension occurred in 65% (26% Grade 3) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with antihypertensive therapy or for hypertensive crisis.

Cardiac Failure: CABOMETYX can cause severe and fatal cardiac failure. Cardiac failure occurred in 0.5% of patients treated with CABOMETYX as a single agent, including fatal cardiac failure in 0.1% of patients. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Withhold and resume at a reduced dose upon recovery or permanently discontinue depending on the severity.

Diarrhea: CABOMETYX can cause diarrhea and it occurred in 62% (10% Grade 3) of treated patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1; resume at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): CABOMETYX can cause PPE and it occurred in 45% of treated patients (13% Grade 3). Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.

Hepatotoxicity: CABOMETYX in combination with nivolumab in RCC can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. Monitor liver enzymes before initiation of treatment and periodically. Consider more frequent monitoring as compared to when the drugs are administered as single agents. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity.

Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity.

Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome.

Osteonecrosis of the Jaw (ONJ): CABOMETYX can cause ONJ and it occurred in <1% of treated patients. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution; resume at a reduced dose.

Impaired Wound Healing: CABOMETYX can cause impaired wound healing. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): CABOMETYX can cause RPLS. Perform evaluation for RPLS and diagnose by characteristic finding on MRI any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Thyroid Dysfunction: CABOMETYX can cause thyroid dysfunction, primarily hypothyroidism, and it occurred in 19% of treated patients (0.4% Grade 3). Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment.

Hypocalcemia: CABOMETYX can cause hypocalcemia, with the highest incidence in DTC patients. Based on the safety population, hypocalcemia occurred in 13% of CABOMETYX patients (2% Grade 3 and 1% Grade 4).

Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume CABOMETYX at a reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity.

Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose.

ADVERSE REACTIONS

The most common (≥20%) adverse reactions are:

CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation.

CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.

Strong or Moderate CYP3A4 Inducers: If coadministration with strong or moderate CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John’s wort.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.

Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment.

Pediatric Use: Physeal widening has been observed in children with open growth plates when treated with CABOMETYX. Physeal and longitudinal growth monitoring is recommended in children (12 years and older) with open growth plates. Consider interrupting or discontinuing CABOMETYX if abnormalities occur. The safety and effectiveness of CABOMETYX in pediatric patients less than 12 years of age have not been established.

Please see accompanying full Prescribing Information https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

About Zanzalintinib
Zanzalintinib is a novel oral kinase inhibitor that inhibits the activity of the TAM kinases (TYRO3, AXL, MER), MET and VEGF receptors. These kinases play important roles in oncogenic processes, including tumor cell proliferation, metastasis, angiogenesis, drug resistance and evasion of antitumor immunity. The zanzalintinib development program includes a series of ongoing and planned pivotal trials to explore its therapeutic potential in CRC, clear cell and non-clear cell RCC, and NET, as well as earlier-stage trials in meningioma, lung cancer and castration-resistant prostate cancer.

In February 2026, Exelixis announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application for zanzalintinib, in combination with atezolizumab (Tecentriq®), for the treatment of adult patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026.

Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis’ planned presentations for cabozantinib and zanzalintinib, including new analyses from the phase 3 CABINET and STELLAR-303 trials, at the 2026 ASCO Annual Meeting; Exelixis’ strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the development of zanzalintinib, its next oncology franchise molecule; Exelixis’ dedication to improving the standards of care for patients with cancer; and Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis’ continuing compliance with applicable legal and regulatory requirements; the potential failure of cabozantinib or zanzalintinib to demonstrate safety and/or efficacy in clinical trials; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib or zanzalintinib; the costs of conducting clinical trials; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of cabozantinib and zanzalintinib; Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis’ marketed products; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption “Risk Factors” in Exelixis’ most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis’ future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis.

TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group.

More News From Exelixis, Inc.

Exelixis remains undervalued despite a 13%+ rally post-Q1, supported by robust double-digit growth, sector-leading profitability, and strong free cash flow. Q1 revenue grew 10% year-over-year, driven almost entirely by CABOMETYX demand; operating margin expanded to 41.1% as costs fell. I maintain a Buy rating with a $57 target, reflecting 13% upside; DCF and peer multiples confirm the valuation gap persists.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 11:05 a.m. ET / 8:05 a.m. PT on Wednesday, June 3 in New York City. Goldman Sachs 47th Annual Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, June 9 in Miami. To access the.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Ridofranz / iStock via Getty Images

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles. With the S&P 500 trading at rich multiples and earnings expectations leaning heavily on tech, investors hunting for under-the-radar names near $50 a share have a reason to look at oncology specialists with real cash flow rather than speculative pipeline-only biotechs.

With that in mind, here is one biotech stock trading near $50 that fits the profile of a defensive growth name analysts believe still has room to run.

Exelixis (NASDAQ: EXEL) Exelixis (NASDAQ:EXEL | EXEL Price Prediction) is an oncology-focused biotechnology company headquartered in Alameda, California, that discovers and commercializes targeted cancer therapies, most notably CABOMETYX in kidney, liver, and thyroid cancers.

Shares trade near $50, after a 12.05% gain over the past month and a 14.15% year-to-date advance. For a retail investor, that price point still buys a profitable mid-cap biotech with a $12.58 billion market capitalization rather than a speculative clinical-stage name.

Fundamentals back up the price action. Q1 2026 non-GAAP EPS came in at $0.87, beating consensus by 14.02%, on revenue of $610.81 million, up 9.97% year over year. Operating income jumped 34.51% and net income climbed 31.86%. That marks four consecutive earnings beats with surprise margins between 14.02% and 17.17%.

The stock trades at a trailing P/E of 17 and a forward P/E of 16, with an analyst target price of $49.65 reflecting one strong buy, nine buy, and nine hold ratings. H.C. Wainwright carries a $54 price target with a Buy rating.

The bull case is straightforward. CABOMETYX is the number one prescribed TKI in renal cell carcinoma, and global cabozantinib franchise revenue grew 12.5% year over year to $764 million in Q1. Management is sitting on roughly $1.4 billion in cash and marketable securities and just authorized a new $750 million buyback running through December 31, 2027, on top of completing the prior $750 million program. Layered on top is the December 3, 2026 PDUFA date for zanzalintinib in previously treated metastatic colorectal cancer, an indication CEO Michael Morrissey called “the top priority for the entire Exelixis, Inc. organization,” with a market opportunity management pegs at approximately $1.5 billion. FY2026 guidance of $2.525 billion to $2.625 billion in total revenue explicitly excludes any zanzalintinib launch contribution, leaving room for upside.

The key risk is concentration. The cabozantinib franchise still generates the overwhelming majority of revenue, and a regulatory delay or rejection of zanzalintinib would remove the most-watched near-term catalyst. Clinical disappointments, such as the LightSpark-012 readout management referenced, are a reminder that “triplet therapy in clear cell renal cell carcinoma is not an easy game.” Generic pressure on cabozantinib later this decade also looms.

With a beta of 0.385, profitable operations, an aggressive buyback, and a binary catalyst landing in December, EXEL looks like the kind of cash-generative oncology name that historically benefits when defensive healthcare comes back into favor.

A share price near $50 is a frame of reference, not a thesis. Concentration risk, FDA outcomes, and broader sector rotation can all move quickly, so readers should treat this as a starting point for their own due diligence rather than a recommendation, and size any position around their own risk tolerance and time horizon.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Exelixis (EXEL - Free Report) Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.

EXEL is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Medical stock. EXEL has a Momentum Style Score of A, and shares are up 15.6% over the past four weeks.

Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.14 to $3.55 per share. EXEL boasts an average earnings surprise of +17%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, EXEL should be on investors' short list.

Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

It has been about a month since the last earnings report for Exelixis (EXEL - Free Report) . Shares have added about 6% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Exelixis, Inc. before we dive into how investors and analysts have reacted as of late.

EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus

Exelixis reported mixed results for the first quarter of 2026.

Adjusted earnings per share (EPS) of 87 cents comfortably beat the Zacks Consensus Estimate of 75 cents. The company posted adjusted EPS of 62 cents in the year-ago quarter. Adjusted earnings exclude the impact of stock-based compensation expenses.

Including stock-based compensation expense, EPS was 79 cents compared with 55 cents in the year-ago period.

The bottom-line growth benefited from lower operating expenses and a decrease in shares outstanding due to ongoing buybacks.

Net revenues of $611 million missed the Zacks Consensus Estimate of $613 million. The top line was up 10% year over year.

EXEL’s Q1 Results in Detail

Net product revenues of $555.0 million were up from $513.3 million in the year-ago quarter. Management attributed the increase to higher sales volume.

Cabometyx (cabozantinib) generated revenues of $552.8 million, which missed the Zacks Consensus Estimate of $558 million and our model estimate of $564 million. The drug is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma.

In March 2025, Exelixis obtained FDA approval for the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET).

The drug was also approved for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET).  

Cometriq (cabozantinib capsules) generated $2.2 million in net product revenues for treating medullary thyroid cancer.  

Collaboration revenues, comprising license and collaboration services revenues, totaled $55.8 million, up 32.4% year over year. The improvement reflected higher royalty revenues from ex-U.S. cabozantinib sales generated by Ipsen and higher milestone-related revenues recognized during the period.

Research and development expenses amounted to $199.9 million, down from $212.2 million in the prior-year quarter due to lower clinical trial and manufacturing costs.

Selling, general and administrative expenses totaled $139.6 million, up 1.8% year over year, primarily due to increases in marketing activities, legal and advisory fees, and personnel expenses.

As of the end of the first quarter of 2026, Exelixis repurchased $590.6 million of its shares under the $750 million share repurchase program (SRP) authorized in October 2025. The company expects to complete the remaining portion of this program in May 2026, ahead of its original commitment to finish by Dec. 31, 2026.

Since initiating its first SRP in March 2023, Exelixis has repurchased a total of $2.59 billion of its common stock, retiring 86.8 million shares at an average price of $29.86 per share as of quarter-end.

In May 2026, the company’s board of directors approved a new $750 million SRP, with authorization extending through Dec. 31, 2027. This marks the sixth SRP launched since March 2023.

EXEL Reaffirms 2026 Guidance

Exelixis has reiterated its guidance for 2026. The company expects total revenues of $2.525-$2.625 billion in 2026. Net product revenues are projected to be in the range of $2.325-$2.425 billion.

Exelixis’ 2026 net product revenue guidance includes a 3.0% increase in wholesale acquisition costs for Cabometyx and Cometriq in the United States, effective Jan. 1, 2026.

The annual guidance excludes any contribution from a potential approval of zanzalintinib in metastatic colorectal cancer (CRC).

Operating expenses are projected to increase. The company expects R&D expenses of $875-$925 million and SG&A expenses of $575-$625 million.

Key Pipeline and Regulatory Updates From EXEL

The company is developing zanzalintinib, a next-generation oral investigational tyrosine kinase inhibitor (TKI).

In February 2026, the FDA accepted EXEL’s new drug application seeking approval of zanzalintinib in previously treated metastatic CRC — in combination  with Tecentriq (atezolizumab). The regulatory body assigned a target action date of Dec. 3, 2026.

The NDA is supported by positive phase III STELLAR-303 data demonstrating a statistically significant reduction in the risk of death compared with Stivarga (regorafenib).

Roche’s Tecentriq is a cancer immunotherapy that is approved around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various types of cancer.

Exelixis is gearing up for the potential first commercial launch of zanzalintinib for the above-mentioned indication.  

A phase III study, STELLAR-304, is evaluating zanzalintinib in combination with Opdivo (nivolumab) versus Sutent (sunitinib) in previously untreated patients with advanced non-clear cell RCC. Top-line results are expected in the second half of 2026, based on current event rates.

Earlier this year, Exelixis collaborated with Natera for the STELLAR-316 study. This phase III study is being sponsored by Exelixis. The study will evaluate zanzalintinib, with and without an immune checkpoint inhibitor, in patients with resected stage II/III CRC.

Patients with CRC who are molecular residual disease (MRD)-positive based on Natera’s Signatera test following completion of definitive therapy — and who have no radiographic evidence of disease — will be eligible for enrollment in the STELLAR-316 trial. Exelixis expects to initiate this study in mid-2026.

Exelixis also collaborated with pharma giant Merck in October 2024 to advance zanzalintinib.

In April 2026, Merck initiated LITESPARK-034, a phase II trial evaluating zanzalintinib plus Welireg (belzutifan) versus Welireg and placebo in previously treated advanced RCC patients who progressed after PD-1/L1 and VEGFR-TKI therapies.

This marks the second Merck-sponsored phase III study under the collaboration, following LITESPARK-033 (launched in December 2025), which is assessing the combination against cabozantinib in first-line advanced RCC post-adjuvant immunotherapy.

Exelixis also announced two additional studies of zanzalintinib — STELLAR-202, a planned phase II trial evaluating the drug in combination with MRK’s blockbuster drug Keytruda (pembrolizumab) as maintenance therapy in squamous non-small cell lung cancer, and a new expansion cohort in the ongoing phase Ib/II STELLAR-002 study assessing zanzalintinib plus docetaxel in metastatic castration-resistant prostate cancer patients with measurable disease. Exelixis plans to launch STELLAR-202 and open the STELLAR-002 expansion cohort in the second half of 2026.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

VGM ScoresCurrently, Exelixis has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the top 40% for value investors.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Exelixis has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerExelixis belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Agios Pharmaceuticals (AGIO - Free Report) , has gained 2.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.

Agios Pharmaceuticals reported revenues of $20.75 million in the last reported quarter, representing a year-over-year change of +137.7%. EPS of -$1.69 for the same period compares with -$1.55 a year ago.

For the current quarter, Agios Pharmaceuticals is expected to post a loss of $1.74 per share, indicating a change of +9.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -4.6% over the last 30 days.

Agios Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.

Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.

EXEL is an oncology company that discovers, develops, and commercializes new treatments for hard-to-treat cancers. Its first-quarter 2026 report showed $611 million in quarterly revenue, GAAP net income of $210.5 million ($0.79 per diluted share), $1.4 billion in cash, along with $430.8 million in repurchases last quarter and another $750 million authorized for more.

It’s no wonder EXEL shares are up 21% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the forward picture of the stock.

Institutional Inflows Finding Exelixis Institutional volumes reveal plenty. In the last year, EXEL has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in EXEL shares. They reflect our proprietary inflow signal, pushing the stock higher:

Source: www.moneyflows.com Plenty of healthcare names are under accumulation right now. But there’s a powerful fundamental story happening with Exelixis.

Exelixis Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, EXEL has had strong sales and earnings growth:

3-year sales growth rate (+13%) 3-year EPS growth rate (+83.6%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +12.4%.

Now it makes sense why the stock has been generating Big Money interest. EXEL has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Exelixis has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Outlier 20 report 29 times, rising 125% since the first outlier inflow signal. The blue bars below show when EXEL was a top pick since 2017…Big Money keeps buying:

Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Exelixis Price Prediction The EXEL action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in EXEL at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.

Related Articles

Gold Price Forecast: Correction Appears Near CompletionOld Dominion’s Increased Demand Drives Big InflowsAI, Institutional Buying Sends Micron Shares Up by 758%About the Author

Lucas is a well-versed equity investor and educator. He currently is co-founder of research and analytics firm, MAPsignals.com, which focuses on finding outlier stocks by following the Big Money.

Editors’ Picks

Comstock Resources, Inc. secures a natural gas supply agreement with NextEra Energy for data center power. Cost reduction efforts in Western Haynesville are ongoing. Low production and transportation costs support CRK's high margins relative to peers.

Posted by Defense World Staff on Apr 5th, 2026

Comstock Resources, Inc. (NYSE:CRK – Get Free Report) has been assigned a consensus rating of “Reduce” from the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.8750.

A number of research firms recently weighed in on CRK. Bank of America lowered shares of Comstock Resources from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $27.00 to $24.00 in a research report on Friday, January 16th. Morgan Stanley set a $19.00 target price on shares of Comstock Resources in a research note on Friday, February 13th. UBS Group set a $17.00 target price on Comstock Resources in a report on Friday, February 13th. Citigroup upped their price target on Comstock Resources from $23.00 to $24.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Mizuho lifted their price objective on Comstock Resources from $21.00 to $29.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th.

Check Out Our Latest Report on Comstock Resources

Comstock Resources Stock Down 0.2% NYSE CRK opened at $19.50 on Friday. The business has a fifty day moving average price of $20.76 and a 200 day moving average price of $21.44. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.49 and a current ratio of 0.49. The company has a market cap of $5.73 billion, a P/E ratio of 13.83 and a beta of 0.39. Comstock Resources has a one year low of $14.65 and a one year high of $31.17.

Comstock Resources (NYSE:CRK – Get Free Report) last announced its earnings results on Wednesday, February 11th. The oil and gas producer reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. The company had revenue of $787.32 million for the quarter, compared to analysts’ expectations of $504.66 million. Comstock Resources had a net margin of 17.80% and a return on equity of 6.30%. The firm’s quarterly revenue was up 115.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.16 EPS. Research analysts anticipate that Comstock Resources will post 0.54 EPS for the current fiscal year.

Insider Transactions at Comstock Resources In other Comstock Resources news, VP Patrick Mcgough sold 48,915 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $21.20, for a total value of $1,036,998.00. Following the completion of the sale, the vice president directly owned 187,516 shares of the company’s stock, valued at $3,975,339.20. This trade represents a 20.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows Several institutional investors and hedge funds have recently modified their holdings of CRK. CreativeOne Wealth LLC increased its position in Comstock Resources by 3.7% during the third quarter. CreativeOne Wealth LLC now owns 13,931 shares of the oil and gas producer’s stock worth $276,000 after purchasing an additional 500 shares during the last quarter. Natixis Advisors LLC boosted its holdings in Comstock Resources by 2.0% in the 4th quarter. Natixis Advisors LLC now owns 29,703 shares of the oil and gas producer’s stock valued at $689,000 after purchasing an additional 572 shares during the last quarter. Carrera Capital Advisors boosted its holdings in Comstock Resources by 0.7% in the 4th quarter. Carrera Capital Advisors now owns 82,910 shares of the oil and gas producer’s stock valued at $1,922,000 after purchasing an additional 606 shares during the last quarter. Uhlmann Price Securities LLC boosted its holdings in Comstock Resources by 2.4% in the 3rd quarter. Uhlmann Price Securities LLC now owns 27,653 shares of the oil and gas producer’s stock valued at $548,000 after purchasing an additional 650 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Comstock Resources by 12.1% in the 4th quarter. GAMMA Investing LLC now owns 6,303 shares of the oil and gas producer’s stock valued at $146,000 after buying an additional 679 shares during the period. Institutional investors and hedge funds own 36.13% of the company’s stock.

About Comstock Resources (Get Free Report)

Comstock Resources, Inc is an independent energy company engaged in the acquisition, exploration, development and production of oil and natural gas properties in the United States. The company focuses on generating long-term value through the efficient development of unconventional resource plays and conventional prospects. Its activities encompass drilling, completion and production operations, as well as the marketing of natural gas, natural gas liquids and crude oil.

Comstock holds a core position in the Haynesville Shale of Northwest Louisiana, one of the most active natural gas plays in North America, and has built a complementary portfolio in the Delaware Basin of West Texas.

Read More Five stocks we like better than Comstock Resources

Receive News & Ratings for Comstock Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock Resources and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESummer Energy (OTCMKTS:SUME) versus AES (NYSE:AES) Critical Comparison

NEXT HEADLINE »Vertex, Inc. (NASDAQ:VERX) Given Average Rating of “Hold” by Analysts

FRISCO, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. (NYSE:CRK) plans to release its first quarter 2026 results on May 5, 2026 after the market closes and host its quarterly conference call at 10:00 a.m. CT on May 6, 2026 to discuss the first quarter results.  

Parties interested in participating in the conference call telephonically will need to register at https://register-conf.media-server.com/register/BIfdab657d67b245688283195b41fda6fb. Upon registering to participate in the conference call, participants will receive the dial-in number and a personal PIN number to access the conference call. On the day of the call, please dial in at least 15 minutes in advance to ensure a timely connection to the call.

~~~

The conference call will also be broadcast live in listen-only mode and can be accessed via the website URL: https://edge.media-server.com/mmc/p/p77w7mi4.

~~~

A replay of the first quarter 2026 conference call will be available for twelve months beginning at 1:00 p.m. CT on May 6, 2026. The replay of the conference can be accessed using the webcast link: https://edge.media-server.com/mmc/p/p77w7mi4.

About Comstock Resources:

Comstock Resources is a leading independent natural gas producer with operations focused on the development of the Haynesville Shale in North Louisiana and East Texas.

A slide show presentation on the financial results will be available on Comstock's website at www.comstockresources.com. Click on “Quarterly Results” to view the slide show.

Posted by Defense World Staff on Apr 25th, 2026

Comstock Resources (NYSE:CRK – Get Free Report) and HKN (OTCMKTS:HKNI – Get Free Report) are both energy companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation This table compares Comstock Resources and HKN”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Comstock Resources $2.22 billion 2.24 $395.61 million $1.41 12.02 HKN N/A N/A N/A N/A N/A Comstock Resources has higher revenue and earnings than HKN.

Profitability This table compares Comstock Resources and HKN’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Comstock Resources 17.80% 6.30% 2.39% HKN N/A N/A N/A Insider & Institutional Ownership 36.1% of Comstock Resources shares are held by institutional investors. 2.2% of Comstock Resources shares are held by insiders. Comparatively, 0.1% of HKN shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations This is a summary of recent ratings and target prices for Comstock Resources and HKN, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comstock Resources 3 6 1 0 1.80 HKN 0 0 0 0 0.00 Comstock Resources presently has a consensus target price of $20.88, suggesting a potential upside of 23.18%. Given Comstock Resources’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Comstock Resources is more favorable than HKN.

Summary Comstock Resources beats HKN on 9 of the 9 factors compared between the two stocks.

About Comstock Resources (Get Free Report)

Comstock Resources, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of natural gas and oil properties in the United States. Its assets are located in the Haynesville and Bossier shales located in North Louisiana and East Texas. The company was incorporated in 1919 and is headquartered in Frisco, Texas. Comstock Resources, Inc. is a subsidiary of Arkoma Drilling, L.P.

About HKN (Get Free Report)

HKN, Inc. operates as an independent energy company. The company owns an oilfield emulsion breaking technology that purifies oilfield emulsions by breaking and separating the emulsions into oil, water, and solids. It also holds non-operated oil and gas leases and mineral interests in properties located in the Bakken and Niobrara shale oil plays; and rights to acreage in the Permian Basin of Texas. The company was founded in 1973 and is based in Southlake, Texas.

Receive News & Ratings for Comstock Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock Resources and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEGlobal Payments Inc. (NYSE:GPN) Receives Average Recommendation of “Hold” from Analysts

NEXT HEADLINE »Meridian Holdings Inc. Common Stock (NASDAQ:MRDN) & CCC Intelligent Solutions Holdings Inc. Common Stock (NASDAQ:CCC) Financial Comparison

Comstock Resources, Inc. (CRK) Q1 2026 Earnings Call Transcript

On June 10, 2026, Comstock Resources Inc CRK shares rose 5.5% today, closing at $13.37. The stock has seen significant fluctuations over the past year, trading in a 52-week range of $12.44 to $31.17.

GF Value™ verdict: Current price of $13.37 is 21.9% below GF Value™ of $17.11, indicating the stock is undervalued.GF Score™: 65/100, suggesting the stock is rated above average in terms of overall quality.Most notable signal: No insider transactions have occurred in the last 3 months. Is CRK Overvalued or Undervalued? The current price of Comstock Resources Inc CRK at $13.37 is significantly below the GF Value™ estimate of $17.11, indicating a 21.9% margin of safety for potential investors. This undervaluation suggests an opportunity, though it is crucial to consider the overall market conditions and the company's financial health. The GF Valuation label categorizes CRK as modestly undervalued, which implies that while there is potential for appreciation, investors should remain cautious due to the inherent risks associated with the oil and gas industry.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. The presence of a modest undervaluation could attract interest, but investors should also be aware of the company’s volatility and external market factors that could influence future performance.

How Does CRK's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)6.2x6.7x Forward P/E20.7xN/A The current P/E (TTM) of 6.2x is 8% below its 5-year median P/E of 6.7x. This indicates that CRK is trading below its historical valuation, which aligns with the GF Value™ verdict of being undervalued. The forward P/E of 20.7x suggests that there may be expectations for increased earnings; however, this figure must be interpreted cautiously given the current market conditions and the company's recent performance.

What Does CRK's GF Score™ Tell Us? MetricRating GF Score™65 Financial Strength4/10 Profitability6/10 Growth6/10 Valuation8/10 Momentum1/10 The GF Score™ of 65/100 indicates that Comstock Resources Inc is positioned above average when compared to its peers. The strongest aspect of CRK's score is its valuation rank of 8/10, reflecting its current status as modestly undervalued. However, it faces challenges in financial strength with a low rating of 4/10, and a concerning momentum rank of 1/10 suggests that the stock may be experiencing weak performance trends. This combination of scores highlights the need for cautious analysis regarding CRK's potential for recovery and growth.

What Are Insiders Doing with CRK Stock? In the last 3 months, there have been no reported insider transactions involving Comstock Resources Inc CRK . The lack of insider activity can suggest that management is either confident in the company's prospects or may be waiting for more favorable conditions before making any moves. For potential investors, this could indicate a degree of caution from insiders regarding the current market environment.

What This Means for Investors Based on the GF Value™ assessment, Comstock Resources Inc CRK is currently undervalued. While the stock presents a potential investment opportunity, it is essential to consider the broader market conditions and the company's financial metrics before making any decisions.

For the complete analysis, visit the Comstock Resources Inc CRK stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is CRK's GF Score™?

The GF Score™ for Comstock Resources Inc is 65/100, indicating that it ranks above average in terms of overall quality compared to its peers.

Is CRK overvalued or undervalued?

CRK is currently undervalued, with a GF Value™ of $17.11 compared to its price of $13.37, presenting a 21.9% margin of safety.

What is CRK's P/E ratio?

CRK's P/E ratio (TTM) is 6.2x, which is 8% below its 5-year median P/E of 6.7x, indicating that the stock is trading below its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Calgary, Alberta--(Newsfile Corp. - April 1, 2026) - Axiom Oil and Gas Inc. ("Axiom" or the "Company") has listed its Manola oil and gas property for sale with Sayer Energy Advisors and has filed a new claim against Tidewater Midstream and Infrastructure Ltd. ("Tidewater") for $1,136,441 plus damages for the seizure and sales of the Company's Manola gas volumes for Tidewater's own account. Axiom cannot assure a potential purchaser of the Manola property that it will be able to access sales gas pipelines and receive any payment for the produced gas wells or solution gas. This new claim is separate, and in addition to Axiom's main claim for $110 million for the Brazeau River action, where Tidewater stranded 6.3 Billion cubic feet natural gas and nearly 1 Million barrels of natural gas liquids reserves despite Axiom paying $4.5 million in advance for a Tidewater sour service plant turnaround that was not performed as scheduled in Apr. 2024, and having a Gas Handling Agreement for "P1" highest priority service for "life of reserves" and no limitation of liability. Axiom has brought the Manola and Brazeau matters to the attention of the Alberta Energy Regulator, and regulatory engagement is ongoing.

Historically, Axiom utilized a Tidewater gas gathering system that transports its Manola sales gas to a Tidewater meter station just north of Edmonton where Tidewater took possession of Axiom's Manola gas. Tidewater has been selling the gas for its own account since October 2024 without reimbursing Axiom upon request. Manola is located approximately 200 km from Brazeau and not is not in any way connected to the Manola operations. Because the Company is not receiving the gas revenue and to preserve its gas wells reserves value, Axiom recently shut in its Manola gas wells and gas plant, while it continues to produce its oil wells.

The Sayer process has bids due Apr. 2, 2026. The link may be found at the following location, and click on Manola

https://www.sayeradvisors.com/view/169/axiom-oil-and-gas-inc.

ABOUT AXIOM OIL AND GAS INC.

Axiom Oil and Gas Inc. is a growth focused Canadian energy company dedicated to generating positive shareholder returns by the responsible development of crude oil and natural gas in the Western Canadian Sedimentary Basin. Combined with an acquisition strategy targeting highly accretive, low decline, complementary opportunities, Axiom has assembled an attractive portfolio of free-cash flowing, low-decline operated assets in Central Alberta.

READER ADVISORY

Forward-Looking Information and Statements

Certain information included in this press release constitutes forward-looking information under applicable securities legislation. Forward-looking information typically contains statements with words such as "anticipate", "believe", "expect", "plan", "intend", "estimate", "propose", "project", "scheduled", "will" or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking information in this press release may include, but is not limited to, the Company's drilling and development plans, cycle times, expectations regarding netbacks, the business plan, cost model and strategy of the Company.

Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date of this update. The Company does not undertake or accept any obligation or undertaking to update or revise any forward-looking statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

All dollar figures included herein are presented in Canadian dollars, unless otherwise noted.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290859

Source: Axiom Oil and Gas Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Posted by Defense World Staff on Apr 15th, 2026

Shares of Tidewater Inc. (NYSE:TDW – Get Free Report) have received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $87.3333.

A number of equities research analysts have recently weighed in on TDW shares. Dawson James restated an “outperform” rating on shares of Tidewater in a research report on Tuesday, March 3rd. Zacks Research upgraded Tidewater from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Raymond James Financial set a $117.00 target price on Tidewater in a research report on Tuesday, March 3rd. Barclays started coverage on Tidewater in a research report on Wednesday, April 1st. They set an “equal weight” rating and a $80.00 target price for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Tidewater in a research report on Monday, December 29th.

View Our Latest Report on TDW

Insiders Place Their Bets In related news, EVP Samuel R. Rubio sold 22,461 shares of Tidewater stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $80.05, for a total transaction of $1,798,003.05. Following the completion of the sale, the executive vice president directly owned 60,066 shares of the company’s stock, valued at $4,808,283.30. The trade was a 27.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel A. Hudson sold 5,195 shares of Tidewater stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $80.56, for a total value of $418,509.20. Following the sale, the executive vice president directly owned 45,971 shares of the company’s stock, valued at approximately $3,703,423.76. This trade represents a 10.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 52,656 shares of company stock valued at $4,079,112. 6.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tidewater Institutional investors have recently made changes to their positions in the stock. VELA Investment Management LLC acquired a new stake in shares of Tidewater during the third quarter worth $1,546,000. Stratos Wealth Advisors LLC acquired a new stake in shares of Tidewater during the third quarter worth $2,010,000. Fulcrum Asset Management LLP grew its stake in shares of Tidewater by 226.1% during the third quarter. Fulcrum Asset Management LLP now owns 33,428 shares of the oil and gas company’s stock worth $1,783,000 after purchasing an additional 23,177 shares during the period. SummerHaven Investment Management LLC acquired a new stake in shares of Tidewater during the third quarter worth $855,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Tidewater by 286.0% during the third quarter. JPMorgan Chase & Co. now owns 187,250 shares of the oil and gas company’s stock worth $9,986,000 after purchasing an additional 138,739 shares during the period. 95.13% of the stock is owned by institutional investors and hedge funds.

Tidewater Trading Down 4.0% Shares of TDW opened at $84.31 on Wednesday. The stock has a fifty day moving average price of $77.61 and a two-hundred day moving average price of $62.45. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.78 and a current ratio of 2.90. Tidewater has a 52-week low of $32.15 and a 52-week high of $89.00. The company has a market cap of $4.18 billion, a price-to-earnings ratio of 12.62 and a beta of 0.56.

Tidewater (NYSE:TDW – Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The oil and gas company reported $4.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $3.64. The firm had revenue of $336.80 million during the quarter, compared to the consensus estimate of $329.39 million. Tidewater had a return on equity of 12.34% and a net margin of 24.74%.The business’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS. Analysts predict that Tidewater will post 3.25 EPS for the current fiscal year.

Tidewater Company Profile (Get Free Report)

Tidewater Inc is a leading global provider of offshore marine support vessels, serving the energy sector with a focus on the oil and gas industry. Headquartered in Houston, Texas, the company operates a diverse fleet of platform supply vessels (PSVs), anchor handling tug supply vessels (AHTSs), crew boats and other specialized vessels designed to support offshore drilling, production and construction activities.

The company’s fleet is equipped to handle a range of maritime services, including the transport of personnel, equipment and bulk materials; anchor handling and mooring operations; and subsea construction support.

Featured Stories Five stocks we like better than Tidewater

Receive News & Ratings for Tidewater Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tidewater and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINENovartis AG (NYSE:NVS) Receives Consensus Rating of “Hold” from Brokerages

NEXT HEADLINE »Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)

The State Street SPDR S&P Oil & Gas Equipment & Services ETF (XES - Free Report) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Energy - Equipment and services segment of the equity market.

While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Energy - Equipment and services is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 1, placing it in top 6%.

Index DetailsThe fund is sponsored by State Street Investment Management. It has amassed assets over $540.92 million, making it one of the average sized ETFs attempting to match the performance of the Energy - Equipment and services segment of the equity market. XES seeks to match the performance of the S&P Oil & Gas Equipment & Services Select Industry Index before fees and expenses.

The S&P Oil & Gas Equipment & Services Select Industry Index represents the oil and gas equipment and services sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX,NASDAQ National Market and NASDAQ Small Cap exchanges. The Oil & Gas Equipment Index is a modified equal weight index.

CostsSince cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.

Annual operating expenses for this ETF are 0.35%, making it one of the least expensive products in the space.

It has a 12-month trailing dividend yield of 1.08%.

Sector Exposure and Top HoldingsIt is important to delve into an ETF's holdings before investing despite the many upsides to these kinds of funds like diversified exposure, which minimizes single stock risk. And, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Energy sector -- about 100% of the portfolio.

Looking at individual holdings, Tidewater Inc (TDW) accounts for about 4.46% of total assets, followed by Seadrill Limited (SDRL) and Technipfmc Plc (FTI).

The top 10 holdings account for about 42.76% of total assets under management.

Performance and RiskThe ETF has gained about 56.82% and is up about 119.3% so far this year and in the past one year (as of 04/29/2026), respectively. XES has traded between $57.24 and $128.22 during this last 52-week period.

The ETF has a beta of 0.91 and standard deviation of 32.99% for the trailing three-year period, making it a high risk choice in the space. With about 35 holdings, it has more concentrated exposure than peers.

AlternativesState Street SPDR S&P Oil & Gas Equipment & Services ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, XES is a great option for investors seeking exposure to the Energy ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well.

iShares U.S. Oil Equipment & Services ETF (IEZ) tracks Dow Jones U.S. Select Oil Equipment & Services Index and the VanEck Oil Services ETF (OIH) tracks MVIS U.S. Listed Oil Services 25 Index. iShares U.S. Oil Equipment & Services ETF has $525.22 million in assets, VanEck Oil Services ETF has $2.47 billion. IEZ has an expense ratio of 0.38%, and OIH charges 0.35%.

Bottom LineTo learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

HOUSTON--(BUSINESS WIRE)--Tidewater Inc. (NYSE:TDW) announced today revenue for the three months ended March 31, 2026 of $326.2 million, compared with $333.4 million for the three months ended March 31, 2025. Tidewater's net income for the three months ended March 31, 2026, was $6.1 million ($0.12 per common share), compared with net income of $42.7 million ($0.83 per common share) for the three months ended March 31, 2025. Quintin Kneen, Tidewater's President and Chief Executive Officer, comme.

Tidewater Inc. (TDW) Q1 2026 Earnings Call Transcript

On May 27, 2026, Tidewater Inc TDW shares fell 4.6% to a current price of $75.09. This decline is notable considering its 52-week range, which has seen a high of $93.13 and a low of $39.48. The stock's recent performance shows a significant one-week drop of 11.2% and a one-month decline of 17.6%, although it has seen a year-to-date increase of 48.7% and a one-year rise of 81.7%.

GF Value™ verdict shows the stock is currently priced at $75.09, which is 9.4% below the GF Value™ estimate of $82.84.GF Score™ is 80/100, indicating a strong overall rating based on key financial metrics.Notable insider activity reveals that insiders sold $2.2 million worth of stock in the last three months, with no purchases reported during the same period. Is TDW Overvalued or Undervalued? The current price of Tidewater Inc TDW at $75.09 is 9.4% below the GF Value™ estimate of $82.84, suggesting that the stock may be undervalued. This margin of safety provides a potential opportunity for investors, as buying shares at a discount to intrinsic value can be appealing. However, it is important to note that the GF Valuation label currently classifies TDW as fairly valued, indicating that while it may appear undervalued relative to the GF Value™, the market may have already priced in certain expectations for future performance.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Given the current market environment and insider selling activity, caution is warranted despite the apparent undervaluation.

How Does TDW's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 12.6x 17.8x Forward P/E 23.8x N/A The current P/E (TTM) of 12.6x is 29% below its 5-year median P/E of 17.8x, indicating that the stock is trading at a lower valuation compared to its historical averages. This analysis aligns with the GF Value™ verdict, suggesting that TDW may indeed be undervalued in the context of its historical performance.

What Does TDW's GF Score™ Tell Us? Metric Rating GF Score™ 80 Financial Strength 7/10 Profitability 5/10 Growth 9/10 Valuation 9/10 Momentum 3/10 The GF Score™ of 80/100 indicates a strong overall performance across various metrics, with the highest score in Growth (9/10) and Valuation (9/10). However, the Momentum score is notably lower at 3/10, suggesting some weakness in the stock's recent price action. The financial strength score of 7/10 reflects a solid balance sheet, while profitability at 5/10 shows room for improvement.

What Are Insiders Doing with TDW Stock? Recent insider activity indicates a bearish sentiment, as insiders sold $2.2 million in stock over the last three months, with no reported buying during the same period. This selling activity may suggest that insiders are not confident in the stock's short-term prospects or are taking profits after a significant price increase over the past year. Such patterns can often signal caution for potential investors.

What This Means for Investors Based on the current GF Value™ assessment, Tidewater Inc TDW appears to be undervalued, trading at 9.4% below its intrinsic value estimate. However, potential investors should remain vigilant, given the insider selling activity and the classification of the stock as fairly valued by GF Valuation. It is crucial to consider these factors before making any investment decisions.

For the complete analysis, visit the Tidewater Inc TDW stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is TDW's GF Score™?

TDW has a GF Score™ of 80/100, indicating a strong performance based on financial metrics that are expected to lead to higher long-term returns.

Is TDW overvalued or undervalued?

TDW is currently undervalued according to GF Value™, as it trades 9.4% below its intrinsic value estimate.

What is TDW's P/E ratio?

TDW's P/E (TTM) ratio is 12.6x, which is significantly below its 5-year median P/E of 17.8x, indicating a lower historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Stuart Essig Appointed as Integra’s Next President and Chief Executive Officer
Michael McBreen Appointed Chief Commercial Officer

PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra’s Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities.

The Company also announced that Michael McBreen, currently executive vice president, president, Codman Specialty Surgical, has been appointed chief commercial officer.

Mr. Essig brings more than thirty years of experience in the medical technology and healthcare industries and has deep familiarity with Integra, having served as chairman of the board since June 2012 and as a director since 1997. He previously served as Integra’s chief executive officer from 1997 through early 2012, and as its President from 1997 until 2010. Over the past two years, Mr. Essig has been actively engaged in the business through his executive chairman role, with direct involvement in key company priorities as well as operational and quality matters.

"Stuart brings unmatched knowledge of Integra, its businesses, and its people," said Barbara Hill, presiding director. "He combines deep institutional knowledge with a clear understanding of the work underway across the organization. We have full confidence in his leadership as Integra accelerates execution, strengthens customer and commercial focus, and builds on the important progress already underway across its priorities for 2026. The Board believes this is the right leadership step for the Company’s next phase, and as such, this is not an interim role, and we do not intend to initiate a CEO search."

"I am honored to once again serve as Integra’s president and CEO," said Mr. Essig. "I return with a clear mandate from the Board and a long-term commitment to lead the Company through its next chapter. In my role as executive chairman, I have seen firsthand the strength of our team and the meaningful progress underway across our priorities, particularly in quality, compliance, operational resilience, and the transformation of the organization.”

Mr. Essig continued, " As I step back into the CEO role, my focus will be on accelerating execution, strengthening our customer and commercial focus, and reinforcing a culture and operating discipline that will drive sustained performance and deliver long-term shareholder value. I know this company, I understand what it takes to run it, and I am deeply committed to leading Integra forward."

Mr. Essig added, "I also want to thank Mojdeh for her numerous contributions to the company and for the meaningful progress made during her tenure. Under her leadership, the Company advanced several important strategic and operational priorities, including enterprise-wide portfolio and program prioritization, risk-based approach to quality remediation work, operational resiliency improvements, and the more recent transformation and business process optimization efforts. These initiatives are progressing well, and we remain fully committed to them.”

As part of this leadership update, the Company also announced that Michael McBreen has been appointed chief commercial officer. In this newly created role, Mr. McBreen will help drive the next phase of Integra’s performance by further elevating the commercial organization and ensuring that customer and market-facing priorities are central to how the Company operates and makes decisions. Both divisions and the entire global commercial structure will report to Mr. McBreen, with his appointment intended to strengthen revenue growth, customer outcomes, and execution across the business.

“Mike is exceptionally well-suited for this role with deep commercial relationships," Mr. Essig said. "He brings more than thirty years of commercial experience in the medical technology industry, and his appointment is an important part of how we move forward. This is a strategic leadership step that will help sharpen execution, strengthen our connection to our customers and markets, and support stronger performance across the Company. Integra intends to lead this next chapter with urgency, transparency, and a clear focus on execution."

Mr. Essig will address the leadership transition during Integra’s first quarter 2026 financial results conference call, which will take place this morning at 8:30 a.m. Eastern time. A live webcast will be available on the Investors section of the Company’s website.

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery, tissue reconstruction, and specialized surgical solutions that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver life-saving care. For the latest news and information, visit www.integralife.com.

Contacts:

Investor Relations
Chris Ward
(609) 772-7736
[email protected]

Media
Laurene Isip
(609) 208-8121
[email protected] 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5adce648-cb01-457f-83ba-c7a1895d1515

Stuart Essig, Chairman and Chief Executive Officer Stuart Essig Appointed as Integra’s Next President and Chief Executive Officer